Ambrx Biopharma Inc. Appoints Daniel O'Connor as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--​Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Daniel O’Connor as Chief Executive Officer.“On behalf of the boa...

Related Keywords

United States ,Katrin Rupalla ,Laurence Watts ,Gwen Schanker ,Daniel Oconnor ,Kate Hermans ,Biologics Epbs ,Imclone Systems ,Ambrx Biopharma Inc ,Boston University ,Advaxis Inc ,Exchange Commission ,Syneos Health ,Lifesci Communications ,Gilmartin Group ,Pharmanet Inc ,Engineered Precision Biologics ,Danielo Connor ,Chief Executive ,Oncosec Medical ,Bracco Diagnostics ,Dickinson School ,Pennsylvania State University ,Ambrx Biopharma ,Engineered Precision ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,